Production of a Lung Surfactant SP-B Mimic
Production of a Lung Surfactant SP-B Mimic
批准号:
6933691
负责人:
Gary Fujii
金额:
$13.8万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2005
资助国家:
美国
项目状态:
已结题
起止时间:
2005-05-01 至 2006-04-30
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Surfactant Protein B (SP-B) is important for the normal functioning of lung surfactant. Using the known three-dimensional structures of proteins which also belong to the "saposin" class, early SP-B models predicted that the disulfide cross-linked, N- and C-terminal domains fold as charged amphipathic helices, and further that these adjacent helices may participate in critical surfactant activities. On a small-scale, we have chemically synthesized a 34 residue, disulfide-linked N-terminal - C-terminal peptide construct (i.e., "Mini-B") that emulates the in vitro - in vivo structure and function of the 79 residue parent protein in lung surfactant lipids. However, scale-up of the synthesis of Mini-B by either chemical synthetic methods or through a bacterial expression system has proven to be problematic. In this SBIR grant application, we propose to address this issue by utilizing a cell-free expression system (CFES) that would facilitate the large-scale production of high-purity Mini-B peptide. Development of a commercially viable production method will permit the use of the Mini-B peptide in biomedical applications, including lung surfactant replacement therapies such as Neonatal Respiratory Distress Syndrome (NRDS), Adult Respiratory Distress Syndrome (ARDS), as well as facilitate the development of novel delivery systems to the lung for antibiotics, anti-inflammatory agents, and genetic material.
期刊论文(4)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1371/journal.pone.0072821
发表时间:
2013
期刊:
PloS one
影响因子:
3.7
作者:
[Sharifahmadian M, Sarker M, Palleboina D, Waring AJ, Walther FJ, Morrow MR, Booth V]
通讯作者:
Booth V
Synthesis and activity of a novel diether phosphonoglycerol in phospholipase-resistant synthetic lipid:peptide lung surfactants().
抗磷脂酶合成脂质中新型二醚膦酰甘油的合成和活性:肽肺表面活性剂()。
DOI:
10.1039/c1md00206f
发表时间:
2011
期刊:
MedChemComm
影响因子:
--
作者:
[Schwan,AdrianL, Singh,SuneelP, Davy,JasonA, Waring,AlanJ, Gordon,LarryM, Walther,FransJ, Wang,Zhengdong, Notter,RobertH]
通讯作者:
Notter,RobertH
VesiVax Vaccine Formulation Against Neisseria gonorrhoeae
-
批准号:10385208
-
项目类别:
-
资助金额:$29.98万
-
财政年份:2022
-
负责人:Gary Fujii
-
依托单位:
VesiVax Vaccine Formulation Against Neisseria gonorrhoeae
-
批准号:10576383
-
项目类别:
-
资助金额:$29.98万
-
财政年份:2022
-
负责人:Gary Fujii
-
依托单位:
Niclosamide Formulations for the Treatment of Influenza Infections
-
批准号:10385194
-
项目类别:
-
资助金额:$29.85万
-
财政年份:2022
-
负责人:Gary Fujii
-
依托单位:
Non-clinical Development of a Synthetic Lung Surfactant for Treatment of NRDS
-
批准号:10432112
-
项目类别:
-
资助金额:$103.18万
-
财政年份:2021
-
负责人:Gary Fujii
-
依托单位:
Non-clinical Development of a Synthetic Lung Surfactant for Treatment of NRDS
-
批准号:10252528
-
项目类别:
-
资助金额:$95.69万
-
财政年份:2021
-
负责人:Gary Fujii
-
依托单位:
Non-clinical Development of a Synthetic Lung Surfactant for Treatment of NRDS
-
批准号:10668735
-
项目类别:
-
资助金额:$6.72万
-
财政年份:2021
-
负责人:Gary Fujii
-
依托单位:
Non-clinical Development of a Synthetic Lung Surfactant for Treatment of NRDS
-
批准号:10672648
-
项目类别:
-
资助金额:$11.34万
-
财政年份:2021
-
负责人:Gary Fujii
-
依托单位:
Optimization of VesiVax® Lipidated Tucaresol Formulations
-
批准号:9131908
-
项目类别:
-
资助金额:$22.5万
-
财政年份:2016
-
负责人:Gary Fujii
-
依托单位:
Pre-clinical Development of a Vaccine for the Treatment of Heroin Addiction
-
批准号:8981051
-
项目类别:
-
资助金额:$22.5万
-
财政年份:2015
-
负责人:Gary Fujii
-
依托单位:
Development of a Gene and Oligonucleotide Delivery System
-
批准号:8981573
-
项目类别:
-
资助金额:$32.29万
-
财政年份:2015
-
负责人:Gary Fujii
-
依托单位:
Design and Engineering of Nanoparticulate Universal Vaccines
-
批准号:8978668
-
项目类别:
-
资助金额:$29.03万
-
财政年份:2015
-
负责人:Gary Fujii
-
依托单位:
Engineering of a Novel CDN Nanoparticle Platform
-
批准号:8782396
-
项目类别:
-
资助金额:$24.59万
-
财政年份:2014
-
负责人:Gary Fujii
-
依托单位:
Novel VLP Adjuvant based on the VesiVax system
-
批准号:8524930
-
项目类别:
-
资助金额:$30.0万
-
财政年份:2013
-
负责人:Gary Fujii
-
依托单位:
Novel VLP Adjuvant based on the VesiVax system
-
批准号:8720689
-
项目类别:
-
资助金额:$30.0万
-
财政年份:2013
-
负责人:Gary Fujii
-
依托单位:
Development of VesiVax Carbohydrate Conjugation Chemistry
-
批准号:8593016
-
项目类别:
-
资助金额:$29.43万
-
财政年份:2013
-
负责人:Gary Fujii
-
依托单位:
Liposomal Nicotine Vaccine Development
-
批准号:8211742
-
项目类别:
-
资助金额:$34.48万
-
财政年份:2011
-
负责人:Gary Fujii
-
依托单位:
ENDPOINTS FOR CORRELATING PROTECTIVE IMMUNITY IN RESPONSE TO INFLUENZA
-
批准号:8357370
-
项目类别:
-
资助金额:$10.48万
-
财政年份:2011
-
负责人:Gary Fujii
-
依托单位:
Genital Herpes Vaccine Discovery
-
批准号:8068125
-
项目类别:
-
资助金额:$19.8万
-
财政年份:2010
-
负责人:Gary Fujii
-
依托单位:
Surrogate endpoints for correlating protective immunity in response to influenza
-
批准号:7608534
-
项目类别:
-
资助金额:$30.0万
-
财政年份:2009
-
负责人:Gary Fujii
-
依托单位:
Thermal Targeting of Antimicrobial Drugs to Sites of Infection
-
批准号:7481628
-
项目类别:
-
资助金额:$30.0万
-
财政年份:2008
-
负责人:Gary Fujii
-
依托单位:
海外基金